Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Mesoblast Limited

http://www.mesoblast.com/

Latest From Mesoblast Limited

Keeping Track: Disappointment For Mesoblast And Aquestive; Opdivo/Yervoy Add Mesothelioma Claim; Pediatric Approvals

The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.

US FDA Performance Tracker Pediatrics

US FDA Approval Activity Could Cool Down In September

With just 10 user fee goal dates coming up, September could be break from the fast pace of FDA decisions over the summer.

US FDA Performance Tracker Drug Review

The Greatest US FDA Advisory Committees: A Look Back At Tumult And Turning Points

With two landmark advisory committee meetings coming up, the Pink Sheet reflects on some of the most memorable panel meetings over the last 20 years.

Advisory Committees FDA

Mesoblast’s Cell Therapy For Pediatric GVHD Gets US Panel Green Light Despite FDA's "Substantial Concerns"

Oncologic Drugs Advisory Committee votes 8-2 that data support efficacy of the product, which could be the first mesenchymal stem cell product to clear the agency. FDA's concerns include reliance on a pivotal Phase III single-arm study.

Advisory Committees Drug Approval Standards
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Drug Delivery
  • Biotechnology
    • Gene Therapy, Cell Therapy
    • Drug Discovery Tools
      • ADMET
  • Other Names / Subsidiaries
    • Angioblast Systems Inc.
UsernamePublicRestriction

Register